Tags

Type your tag names separated by a space and hit enter

An assessment by the Statin Muscle Safety Task Force: 2014 update.
J Clin Lipidol. 2014 May-Jun; 8(3 Suppl):S58-71.JC

Abstract

The National Lipid Association's Muscle Safety Expert Panel was charged with the duty of examining the definitions for statin-associated muscle adverse events, development of a clinical index to assess myalgia, and the use of diagnostic neuromuscular studies to investigate muscle adverse events. We provide guidance as to when a patient should be considered for referral to neuromuscular specialists and indications for the performance of a skeletal muscle biopsy. Based on this review of evidence, we developed an algorithm for the evaluation and treatment of patients who may be intolerant to statins as the result of adverse muscle events. The panel was composed of clinical cardiologists, clinical lipidologists, an exercise physiologist, and a neuromuscular specialist.

Authors+Show Affiliations

Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, USA. Electronic address: robert.rosenson@mssm.edu.McMaster University, Hamilton, ON, Canada.Emory University, Atlanta, GA, USA.Mayo Clinic, Rochester, MN, USA.Department of Cardiology, Henry Low Heart Center, Hartford Hospital, Hartford, CT, USA.No affiliation info available

Pub Type(s)

Journal Article
Practice Guideline

Language

eng

PubMed ID

24793443

Citation

Rosenson, Robert S., et al. "An Assessment By the Statin Muscle Safety Task Force: 2014 Update." Journal of Clinical Lipidology, vol. 8, no. 3 Suppl, 2014, pp. S58-71.
Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58-71.
Rosenson, R. S., Baker, S. K., Jacobson, T. A., Kopecky, S. L., Parker, B. A., & The National Lipid Association's Muscle Safety Expert Panel, . (2014). An assessment by the Statin Muscle Safety Task Force: 2014 update. Journal of Clinical Lipidology, 8(3 Suppl), S58-71. https://doi.org/10.1016/j.jacl.2014.03.004
Rosenson RS, et al. An Assessment By the Statin Muscle Safety Task Force: 2014 Update. J Clin Lipidol. 2014;8(3 Suppl):S58-71. PubMed PMID: 24793443.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An assessment by the Statin Muscle Safety Task Force: 2014 update. AU - Rosenson,Robert S, AU - Baker,Steven K, AU - Jacobson,Terry A, AU - Kopecky,Stephen L, AU - Parker,Beth A, AU - The National Lipid Association's Muscle Safety Expert Panel,, PY - 2014/03/03/received PY - 2014/03/11/accepted PY - 2014/5/6/entrez PY - 2014/5/6/pubmed PY - 2014/12/17/medline KW - Muscle adverse events KW - Myalgia KW - Myopathy KW - Neuromuscular testing KW - Rhabdomyolysis KW - Statin intolerance KW - Statins SP - S58 EP - 71 JF - Journal of clinical lipidology JO - J Clin Lipidol VL - 8 IS - 3 Suppl N2 - The National Lipid Association's Muscle Safety Expert Panel was charged with the duty of examining the definitions for statin-associated muscle adverse events, development of a clinical index to assess myalgia, and the use of diagnostic neuromuscular studies to investigate muscle adverse events. We provide guidance as to when a patient should be considered for referral to neuromuscular specialists and indications for the performance of a skeletal muscle biopsy. Based on this review of evidence, we developed an algorithm for the evaluation and treatment of patients who may be intolerant to statins as the result of adverse muscle events. The panel was composed of clinical cardiologists, clinical lipidologists, an exercise physiologist, and a neuromuscular specialist. SN - 1933-2874 UR - https://www.unboundmedicine.com/medline/citation/24793443/An_assessment_by_the_Statin_Muscle_Safety_Task_Force:_2014_update_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1933-2874(14)00160-3 DB - PRIME DP - Unbound Medicine ER -